The relationship between CD40 gene polymorphism and unstable coronary atherosclerotic plaques

Related Experiment Video

Updated: Jun 12, 2026

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Cuiping Wang1, Jinchuan Yan, Ping Yang

  • 1Division of Cardiology, Department of Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China.

Clinical Cardiology
|June 17, 2010
PubMed

Insights

The CD40 (-1C/T) gene polymorphism, specifically the C allele, is linked to an increased risk of unstable coronary atherosclerotic plaques rupturing. This finding may help identify patients at higher risk for acute coronary syndromes.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Atherosclerosis Research

Background:

  • CD40 gene polymorphism has been associated with acute coronary syndromes.
  • Limited research exists on the link between CD40 polymorphism and vulnerable plaque rupture risk.

Purpose of the Study:

  • To investigate the association between CD40 (-1C/T) gene polymorphism and the risk of coronary atherosclerotic plaque rupture.
  • To determine if specific CD40 genotypes or alleles correlate with plaque morphology and instability.

Main Methods:

  • Coronary angiography was performed on 699 patients, categorized into complex lesions (343), smooth lesions (131), and control (225) groups.
  • CD40 gene polymorphism was analyzed using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP), followed by sequencing.

Main Results:

  • The CC genotype and C allele frequencies of the CD40 gene were significantly higher in the complex lesions group compared to smooth lesions and control groups (P < .001).
  • The TT genotype frequency was significantly lower in the complex lesions group (P < .001).
  • The C allele was associated with an increased risk of plaque disruption in complex lesions (OR: 1.697, 95% CI: 1.273-2.261).

Conclusions:

  • CD40 (-1C/T) polymorphism is associated with unstable coronary atherosclerotic plaques.
  • The presence of the C allele increases the risk of coronary atherosclerotic plaque disruption, contributing to acute coronary syndromes.
Abstract

More Related Videos

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...